| | whole cohort | female | male | ChAdOx/ChAdOx | ChAdOx/Mod | ChAdOx/BNT |
|---|---|---|---|---|---|---|
| whole cohort | 324 | 178 | 146 | 103 | 116 | 105 |
| female | 178 (54.9 %) | | | 54 (52.4 %) | 64 (55.2 %) | 60 (57.1 %) |
| male | 146 (45.1 %) | | | 49 (46.6 %) | 52 (44.8 %) | 45 (42.9 %) |
| ChAdOx/ChAdOx | 103 (31.8 %) | 54 (30.3 %) | 49 (33.6 %) | | | |
| ChAdOx/Mod | 116 (35.8 %) | 64 (36.0 %) | 52 (35.6 %) | | | |
| ChAdOx/BNT | 105 (32.4 %) | 60 (33.7 %) | 45 (30.8 %) | | | |
| Anti-NCP IgG pos. | 9 (2.8 %) | 4 (2.2 %) | 5 (3.4 %) | 2 (1.9 %) | 4 (3.4 %) | 3 (2.9 %) |

**Table S1:** numerical makeup of the cohort, whose data went into statistical analysis. The percentages in the brackets represent the share of the stated number in relation to the total number of participants of the group defined by each column.